The Einstein-Rockefeller-CUNY-Mount Sinai Center for AIDS Research (ERCM-CFAR) synergizes the expertise of over 150 outstanding basic, clinical, translational, behavioral, implementation, and public health investigators from three major academic institutions at the forefront of HIV/AIDS research: Albert Einstein College of Medicine, Rockefeller University, City University of New York (CUNY) and the Icahn School of Medicine at Mount Sinai. Our scientific affinity for and long-standing commitment to HIV/AIDS research are consequences of our New York City location, which was one of the first epicenters of the HIV pandemic almost 40 years ago. There are over 128,000 people with HIV in NYC, the highest number in any city in the country, and the site of four of the 48 counties with the highest number of new HIV diagnoses targeted by the United States federal government Ending the HIV Epidemic in the U.S. plan.
By the Numbers
The Einstein-Rockefeller-CUNY-Mount Sinai Center for AIDS research (ERCM-CFAR) is one of 20 Centers for AIDS Research (CFAR) funded by the National Institutes of Health.
-
$44.5M
in funding from the National Institutes of Health Office of AIDS Research
-
160
investigators
-
>1,250
HIV/AIDS-related published papers*
-
5
research and operational cores
-
>6,200
people living with HIV in active care in our Clinical Cohort Database
Video could not be played
Make a Gift
We need your help to end the HIV epidemic by supporting our efforts to develop highly innovative new treatments to cure HIV infection, treat HIV infection and prevent HIV infection. To make a donation, please contact us at 718-430-2740 or email Sonya Rusanov, MPH, ERCM-CFAR program administrator, at sonya.rusonav@einsteinmed.edu.
Recent Publications
-
Menopausal hormone therapy and subclinical cardiovascular disease in women with and without HIV
-
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
-
ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx
-
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx
-
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD